PTK2 and hepatocellular carcinoma: Inhibition of adaptively activated FAK, along with its downstream targets AKT and cholesterol biosynthesis, using the FAK inhibitor defactinib, effectively reverses sorafenib resistance in HCC cells (Fig. 8H).